Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD – London, United Kingdom - Online CME

We have entered a new era for treatment of cardiorenal disease in diabetes. Prof. John Deanfield discusses evidence on the need for early management and alteration of upstream factors that affect renal and cardiac function in diabetic patients.

Video navigation menu

Diabetes strongly impacts the risk of CVD and life expectancy, partly through risk of renal complications 0:26
Novel treatments that can improve cardiorenal outcomes in diabetes 3:05
Prevention of cardio-renal disease in diabetes 7:00
Effect of early intervention on common pathway to disease 10:02
Emerging early role for new drugs 12:26

Educational information

This lecture by prof. John Deanfield was part of a CME accredited symposium " Impacting progression and outcomes of DKD: Translating novel insights with GLP-1 RA to practice" held during ERA EDTA 2019 in Budapest, Hungary.

Faculty

Prof. Deanfield - Professor of Cardiology at University College London (UCL) and Consultant Cardiologist at the Barts Heart Centre (BHC) London UK. He is the Director of the National Centre for Cardiovascular disease Prevention and Outcomes (NCCPO) at UCL, and Chairman of National Institute for Cardiovascular (CV) Outcomes Research (NICOR)

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk.

View slides of the presentation

Online-CME

This is available as accredited online CME for members. Click the button below to enroll:

Enroll

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.